Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 25,161 followers.

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience https://t.co/hv3kKaqSe9 https://t.co/dWpOa6Vefc

16 Nov 2022

Reply Repost Favourite

New research: Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience: Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple… https://t.c

15 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.